Radiation Oncology

Stage III

Questions discussed in this category

Should durvalumab consolidation still be offered to Stage III NSCLC patients with PD-L1< 1%?

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

3 Answers available

Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

2 Answers available

For patients with inoperable stage III NSCLC who are unable to receive or refuse definitive chemoradiation, how do you decide among radiation alone, pembrolizumab alone, or radiation followed by either pembrolizumab or durvalumab?

5 Answers available

Would you offer the PACIFIC protocol to a patient with stage III lung cancer with performance status 2-3?

If so, how would you modify this regimen?

1 Answer available

For stage III NSCLC treated with definitive intent chemoRT, how do you decide to proceed with surgery vs consolidation immunotherapy?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Lancet (London, England), 2009-08-01

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

International journal of radiation oncology, biology, physics, 2015-09-01

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

Future Oncol, 2019 Apr 25

Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.

Related Topics in Radiation Oncology